Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HBB | P68871 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16555194 | 0.80 | HIF1A (0.37) | HIF1AMEN1LMNABLMHBB | |
| SCHEMBL20919831 | 0.78 | TET2 (0.40) | HIF1AMEN1LMNABLMHBB | |
| SCHEMBL4303348 | 0.76 | HIF1A (0.44) | HIF1AMEN1LMNABLMHBB | |
| SCHEMBL22804847 | 0.75 | NPSR1 (0.39) | MEN1KMT2ATSHRALDH1A1CYP2C19 | |
| SCHEMBL28602898 | 0.74 | MEN1 (0.40) | HIF1AMEN1LMNABLMHBB | |
| SCHEMBL28215158 | 0.72 | CYP4F2 (0.46) | ALDH1A1KDM4E | |
| SCHEMBL17647425 | 0.71 | ALDH1A1 (0.38) | HIF1AMEN1LMNABLMHBB | |
| SCHEMBL12378591 | 0.71 | KDM4E (0.46) | HIF1AMEN1LMNABLMHBB | |
| SCHEMBL2020575 | 0.70 | — | — | |
| SCHEMBL3814475 | 0.70 | TSHR (0.40) | HIF1AMEN1LMNABLMHBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| CN-101389628-B | Indolopyridines as EG5 kinesin modulators | 4SC AG | 2013-02-27 | — | — | CN | disclosed |
| EP-2445902-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | HIF1A 2125/4885MEN1 1146/4885LMNA 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.